Javascript must be enabled to continue!
Smoc2 modulates embryonic myelopoiesis during zebrafish development
View through CrossRef
Background: SMOC2 is a member of the BM‐40 (SPARC) family of matricellular proteins, reported to influence signaling in the extracellular compartment. In mice, Smoc2 is expressed in many different tissues and was shown to enhance the response to angiogenic growth factors, mediate cell adhesion, keratinocyte migration, and metastasis. Additionally, SMOC2 is associated with vitiligo and craniofacial and dental defects. The function of Smoc2 during early zebrafish development has not been determined to date. Results: In pregastrula zebrafish embryos, smoc2 is expressed ubiquitously. As development progresses, the expression pattern becomes more anteriorly restricted. At the onset of blood cell circulation, smoc2 morphants presented a mild ventralization of posterior structures. Molecular analysis of the smoc2 morphants indicated myelopoietic defects in the rostral blood islands during segmentation stages. Hemangioblast development and further specification of the myeloid progenitor cells were shown to be impaired. Additional experiments indicated that Bmp target genes were down‐regulated in smoc2 morphants. Conclusions: Our findings reveal that Smoc2 is an essential player in the development of myeloid cells of the anterior lateral plate mesoderm during embryonic zebrafish development. Furthermore, our data show that Smoc2 affects the transcription of Bmp target genes without affecting initial dorsoventral patterning or mesoderm development. Developmental Dynamics 243:1375–1390, 2014. © 2014 Wiley Periodicals, Inc.
Title: Smoc2 modulates embryonic myelopoiesis during zebrafish development
Description:
Background: SMOC2 is a member of the BM‐40 (SPARC) family of matricellular proteins, reported to influence signaling in the extracellular compartment.
In mice, Smoc2 is expressed in many different tissues and was shown to enhance the response to angiogenic growth factors, mediate cell adhesion, keratinocyte migration, and metastasis.
Additionally, SMOC2 is associated with vitiligo and craniofacial and dental defects.
The function of Smoc2 during early zebrafish development has not been determined to date.
Results: In pregastrula zebrafish embryos, smoc2 is expressed ubiquitously.
As development progresses, the expression pattern becomes more anteriorly restricted.
At the onset of blood cell circulation, smoc2 morphants presented a mild ventralization of posterior structures.
Molecular analysis of the smoc2 morphants indicated myelopoietic defects in the rostral blood islands during segmentation stages.
Hemangioblast development and further specification of the myeloid progenitor cells were shown to be impaired.
Additional experiments indicated that Bmp target genes were down‐regulated in smoc2 morphants.
Conclusions: Our findings reveal that Smoc2 is an essential player in the development of myeloid cells of the anterior lateral plate mesoderm during embryonic zebrafish development.
Furthermore, our data show that Smoc2 affects the transcription of Bmp target genes without affecting initial dorsoventral patterning or mesoderm development.
Developmental Dynamics 243:1375–1390, 2014.
© 2014 Wiley Periodicals, Inc.
Related Results
Suppression of SMOC2 alleviates myocardial fibrosis via the ILK/p38 pathway
Suppression of SMOC2 alleviates myocardial fibrosis via the ILK/p38 pathway
BackgroundFibrosis of the myocardium is one of the main pathological changes of adverse cardiac remodeling, which is associated with unsatisfactory outcomes in patients with heart ...
METTL3 silencing suppresses cardiac fibrosis via m6A modification of SMOC2
METTL3 silencing suppresses cardiac fibrosis via m6A modification of SMOC2
Abstract
Cardiac fibrosis leads to decreased cardiac compliance, impaired systolic and diastolic function, resulting in heart failure. M6A methylation plays a role in fibro...
rno‐miR‐90 promotes chondrogenic differentiation of bone marrow mesenchymal stem cells by targeting SPARC‐related modular calcium binding 2
rno‐miR‐90 promotes chondrogenic differentiation of bone marrow mesenchymal stem cells by targeting SPARC‐related modular calcium binding 2
AbstractBone marrow mesenchymal stem cells (BMSCs) have the ability to differentiate into chondrocytes. In the differentiation of BMSCs into chondrocytes, micro‐RNAs (miRNAs) play ...
Analysis of SMOC2 gene variants in familial and non-familial primary open angle glaucoma Pakistani patients
Analysis of SMOC2 gene variants in familial and non-familial primary open angle glaucoma Pakistani patients
AIM: To find out the association of secreted protein acidic and rich in cysteine (SPARC)-related modular calcium binding 2 (SMOC2) gene variants rs2255680 and rs13208776 with genot...
Alternatives in Animal Research: The Zebrafish Option
Alternatives in Animal Research: The Zebrafish Option
The utilisation of animals in scientific research has been a longstanding subject of debate, with concerns about animal welfare and ethics. In response, researchers have been inves...
Abstract 1273: Adaptive immunity in a zebrafish model of melanoma.
Abstract 1273: Adaptive immunity in a zebrafish model of melanoma.
Abstract
The recent success of the anti-CLTA-4 antibody, ipilimumab, for late stage metastatic melanoma, provides proof of principle that stimulating the immune syst...
Abstract 1581: Tumor suppressor functions of the zebrafish ink4ab: a novel cyclin-dependent kinase inhibitor.
Abstract 1581: Tumor suppressor functions of the zebrafish ink4ab: a novel cyclin-dependent kinase inhibitor.
Abstract
The human INK4b-ARF-INK4a genetic locus encodes two closely related members of the INK4 family of cyclin dependent kinase inhibitors, p15INK4b and p16INK4a ...
Abstract B007: Patterns and quantitation of migration and metastasis in a zebrafish xenograft model of ewing sarcoma
Abstract B007: Patterns and quantitation of migration and metastasis in a zebrafish xenograft model of ewing sarcoma
Abstract
Ewing sarcoma (ES) is one of the most common and lethal pediatric cancers with a 5-year survival rate of less than 30% for those with metastatic disease. Ap...

